ESPR vs. YCBD

Last updated Apr 1, 2026

Compare and contrast key facts about Esperion Therapeutics, Inc. (ESPR) and cbdMD, Inc. (YCBD).

Performance

ESPR vs. YCBD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Esperion Therapeutics, Inc. (ESPR) and cbdMD, Inc. (YCBD). The values are adjusted to include any dividend payments, if applicable.

ESPR vs. YCBD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
ESPR Esperion Therapeutics, Inc.	-25.95%	68.18%	-26.42%	-52.01%	24.60%	-80.77%	-56.40%	38.00%
YCBD cbdMD, Inc.	-45.04%	-55.00%	-63.94%	-89.82%	-78.98%	-63.39%	30.53%	-59.28%

Fundamentals

Market Cap ESPR : $779.73M YCBD : $6.68M
EPS ESPR : -$0.10 YCBD : -$41.47
PS Ratio ESPR : 1.54 YCBD : 0.00
Total Revenue (TTM) ESPR : $403.14M YCBD : $5.03B
Gross Profit (TTM) ESPR : $119.19M YCBD : $3.01B
EBITDA (TTM) ESPR : $62.77M YCBD : -$286.79M

Returns By Period

In the year-to-date period, ESPR achieves a -25.95% return, which is significantly higher than YCBD's -45.04% return.

ESPR

• 1D: 4.18%
• 1M: -18.21%
• YTD: -25.95%
• 6M: 3.40%
• 1Y: 90.28%
• 3Y*: 19.89%
• 5Y*: -37.49%
• 10Y*: -16.92%

YCBD

• 1D: 12.77%
• 1M: -19.07%
• YTD: -45.04%
• 6M: -38.68%
• 1Y: -59.67%
• 3Y*: -78.05%
• 5Y*: -77.98%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ESPR vs. YCBD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ESPR

ESPR Risk / Return Rank: 74
ESPR Sharpe Ratio Rank: 77
ESPR Sortino Ratio Rank: 76
ESPR Omega Ratio Rank: 71
ESPR Calmar Ratio Rank: 74
ESPR Martin Ratio Rank: 72

YCBD

YCBD Risk / Return Rank: 32
YCBD Sharpe Ratio Rank: 28
YCBD Sortino Ratio Rank: 49
YCBD Omega Ratio Rank: 46
YCBD Calmar Ratio Rank: 15
YCBD Martin Ratio Rank: 25

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ESPR vs. YCBD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and cbdMD, Inc. (YCBD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ESPR	YCBD	Difference
Sharpe ratio Return per unit of total volatility	1.09	-0.29	+1.38
Sortino ratio Return per unit of downside risk	1.85	0.76	+1.09
Omega ratio Gain probability vs. loss probability	1.22	1.08	+0.13
Calmar ratio Return relative to maximum drawdown	1.68	-0.75	+2.42
Martin ratio Return relative to average drawdown	3.82	-0.96	+4.78
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ESPR vs. YCBD - Sharpe Ratio Comparison

The current ESPR Sharpe Ratio is 1.09, which is higher than the YCBD Sharpe Ratio of -0.29. The chart below compares the historical Sharpe Ratios of ESPR and YCBD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ESPR	YCBD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.09	-0.29	+1.38
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.42	-0.59	+0.17
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.20	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.15	-0.54	+0.39

Correlation

The correlation between ESPR and YCBD is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ESPR vs. YCBD - Dividend Comparison

Neither ESPR nor YCBD has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ESPR vs. YCBD - Drawdown Comparison

The maximum ESPR drawdown since its inception was -99.37%, roughly equal to the maximum YCBD drawdown of -99.98%. Use the drawdown chart below to compare losses from any high point for ESPR and YCBD.

Drawdown Indicators

	ESPR	YCBD	Difference
Max Drawdown Largest peak-to-trough decline	-99.37%	-99.98%	+0.61%
Max Drawdown (1Y) Largest decline over 1 year	-48.23%	-82.35%	+34.12%
Max Drawdown (5Y) Largest decline over 5 years	-97.46%	-99.97%	+2.51%
Max Drawdown (10Y) Largest decline over 10 years	-99.10%	—	—
Current Drawdown Current decline from peak	-97.62%	-99.97%	+2.35%
Average Drawdown Average peak-to-trough decline	-69.54%	-82.01%	+12.47%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.62%	64.13%	-42.51%

Volatility

ESPR vs. YCBD - Volatility Comparison

The current volatility for Esperion Therapeutics, Inc. (ESPR) is 27.56%, while cbdMD, Inc. (YCBD) has a volatility of 29.79%. This indicates that ESPR experiences smaller price fluctuations and is considered to be less risky than YCBD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ESPR	YCBD	Difference
Volatility (1M) Calculated over the trailing 1-month period	27.56%	29.79%	-2.23%
Volatility (6M) Calculated over the trailing 6-month period	57.36%	122.66%	-65.30%
Volatility (1Y) Calculated over the trailing 1-year period	83.33%	204.70%	-121.37%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	89.13%	131.74%	-42.61%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.10%	126.81%	-43.71%

Financials

ESPR vs. YCBD - Profitability Comparison

The chart below illustrates the profitability comparison between Esperion Therapeutics, Inc. and cbdMD, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ESPR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 168.45M. Therefore, the gross margin over that period was 0.0%.

YCBD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, cbdMD, Inc. reported a gross profit of 3.00B and revenue of 5.02B. Therefore, the gross margin over that period was 59.8%.

ESPR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Esperion Therapeutics, Inc. reported an operating income of 85.23M and revenue of 168.45M, resulting in an operating margin of 50.6%.

YCBD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, cbdMD, Inc. reported an operating income of -286.29M and revenue of 5.02B, resulting in an operating margin of -5.7%.

ESPR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Esperion Therapeutics, Inc. reported a net income of 61.83M and revenue of 168.45M, resulting in a net margin of 36.7%.

YCBD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, cbdMD, Inc. reported a net income of -324.60M and revenue of 5.02B, resulting in a net margin of -6.5%.